||ORD SHS $0.25
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Astrazeneca Share Discussion Threads
Showing 10026 to 10045 of 10050 messages
|............. Re Cancer drugs , proteomics and genomics .................
I choose them because they are where the money is at
If you do some research you will find that many celebrities have undergone surgery to remove various parts of their body in order to avoid the onset of a cancer type.
They have done this because they have tested positive for an inherited genetic mutated gene which recent molecular diagnostic testing has proved to be linked to certain cancer types and subsets.
Thus since we all know at present no cure for any cancer using drugs exists
Then this also proves that the continued development of drugs which target tumors is a waste of time re finding a cure.
However some new drugs do extend life by several months eg circa from 12 months to perhaps eighteen months
The quality of this extended life does not get mentioned much
My point is that the rich celebrities spend money on cancer preventative operations because they have the money and specialist guidance to do so.
A cure for cancer will not be found by trying to attack a developed tumor
The cure will be to attack and remove the mutated genes that cause it|
|Posted this on the BVXP board but will be of interest to holders here for obvious reasons:
While both stocks appear to be worth buying, AstraZeneca’s lower valuation and lower risk profile makes it the superior stock for the long term. Its shares could continue to beat the FTSE 100, as they have done by 9% over the last year.
|Deutsche Bank just came out with £62 target fwiw.|
|Still waiting for £52. Won't be today.|
|Up on drug trial results re sugar reduction for Type 2 diabetics.|
|Good day and a nice dividend received into the account :-)|
|(ShareCast News) - Jefferies upgraded AstraZeneca to 'buy' from 'hold' and lifted the price target to 5,800p from 5,400p saying it sees a much higher probability of success and larger market opportunity from the MYSTIC study than consensus implies.
The MYSTIC study is a global, phase 3 study of the combination of the anti-PD-L1 drug durvalumab and anti CTLA-4 drug tremelimumab in first-line lung cancer.
"We see positive asymmetry on the outcome of MYSTIC, which we expect any time from February 2017. We see around 39% upside if MYSTIC meets our expectations against 10% downside if the entire durva/ treme opportunity in non-small cell lung cancer (NSCLC) is removed.
|Potential reaction on AstraZeneca (AZN) to analysts' perspective in the company's stock
|Clinton going to hammer pharma's.|
|XD today 90c equals 69.5p at current xrates.|
|Helen Thomas Verified account @helentbbc 47 minutes ago
Helen Thomas Retweeted j l
Take note those bidding up AstraZeneca stock on back of Bristol failure.
'Bristol-Myers Plunges on Shocking Cancer Immunotherapy Lung Cancer Study Failure'
|GSK as well !
strong $ after non-farm payroll number . US interest rate hike nearer.|
The £ was lower, is creeping up, and the world continues to spin .|
|us asset strippers on brexit crash? (same happened to arm with japanese)|
|U.K. PLC is open for business (up for sale!) !!|
|So .....a plot could be thickening !|
|Novatis...is also a strong possibility with a market cap maybe 3/4 times greater?|
|IMHO, takeover rumours again. It would make sense for a US company to buy AZN with sterling at such a low level.
Previous offer from Pfizer was £55 and it failed because Azn wanted 59. Now they can bite the cherry at 59 at no cost to them as their cost would be lower at 1.31 E/Rate|
|No idea and hopefully .|
|Any ideas what's happening here? Something brewing|